# A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain

> **NCT00411307** · PHASE2 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 50 (actual)

## Conditions studied

- Pain, Postoperative
- Orthopedic Procedures
- Analgesia

## Interventions

- **DRUG:** OROS hydromorphone HCI

## Key facts

- **NCT ID:** NCT00411307
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2001-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2010-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411307, "A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00411307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*